Chemistry

Photo

Integrated Continuous Manufacturing in Pharmaceuticals

An innovative manufacturing platform called integrated continuous manufacturing (ICM) represents a completely modernized model for drug manufacturing. In contrast to batch processes, ICM’s unique operational advantages will allow for cost-competitive end-to-end manufacturing and enable a more robust and responsive supply chain for critical drugs.

Photo

A New Standard of Collaboration for the Pharmaceutical Industry

Headquartered in Cramlington, UK, Sterling Pharma Solutions is a contract development and manufacturing organization (CDMO) that provides a range of services to the global biopharmaceutical industry, including active pharmaceutical ingredient (API) development, scale-up and cGMP manufacturing, as well as antibody drug conjugate (ADC) R&D and clinical-scale GMP manufacturing.

Photo

The Future of mRNA Technology

mRNA-based vaccines against the coronavirus have become firmly established in medicine since the pandemic. Nevertheless, the technology is still at the beginning of its potential. Experts see a wide range of potential applications for this relatively new technology, particularly in infectious diseases and cancer.

Photo

Bakelite Acquires LRBG Chemicals

Bakelite Synthetics, the US manufacturer of phenolic resins and adhesives, acquires LRBG Chemicals, a Canadian manufacturer and developer of resins based in Longueuil, Quebec.

Photo

Johnson Matthey Set to Catalyze the Net Zero Transition

Johnson Matthey (JM) looks back at a legacy of 200+ years. Established in 1817, the London, England-based chemical company reported annual revenues of about €18 billion in 2022. JM has built a global presence with operations in more than 30 countries. The company’s strategy is based on the vision for a cleaner, healthier world and mirrors society’s need to create a more sustainable future. JM has set out to catalyze the net zero transition by delivering sustainable solutions to customers enabled by innovative technology and leading positions in JM’s key markets automotive, chemicals, and energy. To get a better understanding of the role JM’s technological developments play for a sustainable future, Michael Reubold spoke with Maurits van Tol, the company’s Chief Technology Officer.

Photo

Small Particles with a Big Impact

In 2022, the European Commission revised the definition of nanomaterials in a new recommendation, which supports a uniform EU regulatory framework and aims at aligning the legislation across various sectors. Therefore, particle product design is an enabling technology relevant for many sectors, such as chemicals, consumer products, foods and beverages, health, energy, and the environment.

Photo

Rewriting the Rules for Chemical Distribution

Having survived the pandemic so far in good condition, chemical distributors are well positioned to grow, provided they understand how the rules for winning have changed. Distributors that keep their customers’ needs front and center will be best positioned to succeed, regardless of what the future brings.

Photo

Proactive Supplier Risk Mitigation for Manufacturing and Testing Organizations

There is a new urgency in the market for manufacturers and testing organizations to be prepared for rapid, unexpected changes in material resource access, exacerbated by turbulent regional and global events. This focus is in addition to reinforcing routine risk mitigation activities around the raw material supply chain, adding to the relevance and impact of the topic.

Photo

Planning for the Unexpected

Dorothee Arns, Director General of FECC, discusses current challenges, market trends and her vision for the chemical distribution industry in Europe. The interview was conducted by Michael Reubold and Ralf Kempf.

Photo

Shaping the Future of the Pharma Industry

The International Society for Pharmaceutical Engineering (ISPE) announced the 2022 Facility of the Year Awards (FOYA) Category Winners – including an Honorable Mention for Iovance Biotherapeutics, to be the first company in the world to commercially produce a personalized therapy for solid tumors.

536 more articles

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.